RIGL Stock Analysis: Buy, Sell, or Hold?
RIGL - Rigel Pharmaceuticals Inc. (New)
$45.89
0.64 (1.41%)
▲
5d:
+7.77%
30d:
+24.63%
90d:
+57.21%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When RIGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RIGL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RIGL shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$75.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$47.18
2.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RIGL is currently trading at $45.89, which is considered extended relative to its 30-day fair value range of $37.74 to $43.16. From a valuation perspective, the stock is trading at a premium (Forward PE: 8.8) compared to its historical average (7.9). At these levels, the market is pricing in 3.8% annual earnings growth.
Technical Outlook: Technically, RIGL is in a strong uptrend. Immediate support is located at $39.90, while resistance sits at $47.34.
Market Sentiment: RIGL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $61.20 (+40.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RIGL is in a strong uptrend. Immediate support is located at $39.90, while resistance sits at $47.34.
Market Sentiment: RIGL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $61.20 (+40.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$37.74 -
$43.16
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.2%
Protect Your Profits
Holding RIGL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+6.3% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.3% below Wall St target ($61.20)
- BULLISH: Expecting earnings turnaround to 3.8% growth with -22.6% revenue growth
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$37.74 -
$43.16
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.32
(7.2%)
Support & Resistance Levels
Support Level
$39.90
Resistance Level
$47.34
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.83
Wall Street Target
$61.20
(+40.3%)
Revenue Growth (YoY)
-22.6%
Earnings Growth (YoY)
-73.2%
Profit Margin
116.3%
Valuation Premium vs History
+3.8% premium
PE vs Historical
8.8 vs 7.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.8%
(market-implied from PE analysis)
1-Year Target
$45.28
(+4%)
2-Year Target
$47.00
(+8%)
3-Year Target
$48.78
(+12%)
3-Yr Target (if PE normalizes)
(PE: 9→8)
PE COMPRESSION
$43.64
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 39.4%)
$269.18
(+517%)
Base:
(SPY PE: 8.8, Growth: 39.4%)
$118.21
(+171%)
Bear:
(PE: 7.5, Growth: 39.4%)
$100.48
(+130%)
📈
Valuation based on Current Earnings
Trailing PE: 2.52 | Current EPS (TTM): $16.82
Bull Case
$23.35
(-49%)
Analyst growth -50.0%, PE expands to 2.8
Base Case
$21.23
(-54%)
Market implied -50.0%, PE stable at 2.5
Bear Case
$28.87
(-37%)
Severe decline -20.0%, PE contracts to 2.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 2:05 AM ET
Data refreshes hourly during market hours. Next update: 3:05 AM
Data refreshes hourly during market hours. Next update: 3:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RIGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |
Advanced RIGL Option Strategies
Professional options setups generated by AI based on today's RIGL price and gamma walls.
